
pm et
summari compani largest distributor health care product servic
office-bas dental medic veterinari practition
price-to-earnings oper ep
risk assess reflect histori consist
annual oper earn growth greater
everi year sinc stabl oper margin
balanc increas depend
acquisit sustain earn growth particularli
organ growth dental consum slow
feb ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
ytd revenu yoy
growth broad-bas dental
revenue grow yoy anim health
yoy medic yoy
also saw materi jump sale
technolog segment yoy follow
format practic manag
softwar jv internet brand
own think technolog jv
unlock power cross-sel opportun
suppli busi tradit
incom yoy mainli due higher
restructur cost interest expens
year ytd interest cost yoy
driven increas debt
think relat upcom spin-off
anim segment expect
complet late spin-off pay
dividend back expect
significantli lower leverag
follow transact
materi restructur cost
last quarter support
practic exclud charg
oper incom growth metric
remark steadi grower
posit revenu oper incom
growth everi year sinc admir
reliabl compani lead market
share office-bas dental medic
anim health suppli distribut practic
manag softwar remain cautiou
share howev mainli valuat
also concern regard
upcom anim health spin-off think
deal may mostli leverag
spin-off order pay larg dividend
see reason anim health
success separ
busi success grown
togeth mani year risk view
includ weaker-than-expect demand end
market increas competit
e-commerc player on-go litig
target price ep estim
-- line long-term averag
forward price-to-earnings estim trade
materi premium forward
price-to-earnings despit hsic slower growth outlook
index view base
premium think share alreadi
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
vice-president corpor financ
senior vice presid
corpor overview largest distributor health care product servic
office-bas health care practition compani suppli dental practic physician practic
veterinari clinic suppli might need dental handpiec anim pharmaceut
x-ray machin compani also provid practic manag softwar solut
hsic primari busi distribut segment account revenu
oper profit distribut includ dental product gener total sale
anim health product medic product distribut segment
achiev oper margin yoy oper profit growth two-third total sale
gener remaind intern
technolog segment primarili sell practic manag softwar dental veterinari medic
practic account revenu oper profit technolog segment
achiev oper margin y/i oper profit growth
market profil health care product distribut industri relat office-bas
practition encompass dental anim health medic market produc estim
revenu global compani estim due part inabl store manag larg
quantiti suppli offic distribut health care suppli small equip
office-bas practition character frequent small quantiti order need rapid
reliabl order fulfil
industri continu experi growth due age popul prolifer medic
technolog amongst expand global middl class increas health dental insur
coverag addit physician market continu benefit shift procedur
diagnost test acute-car set alternate-car site particularli physician offic
recent year seen health care industri increasingli focus cost contain
fuel growth hmo group practic collect buy group addit emphasi
obtain product competit price collabor tend favor distributor capabl
provid special manag inform support trend benefit distributor
provid broad array product low price technolog solut improv care deliveri
also led mani distributor limit financi oper market resourc combin
larger compani provid growth opportun
competit landscap compet highli fragment custom base
distributor well sever manufactur dental medic anim health product
sell direct end-us primari competit factor industri price breadth product line
custom servic market scale value-ad servic on-cal repair fleet practic
sale dental product primari competitor patterson benco dental suppli
anim health market primari competitor primari competitor
sale medic product medlin
corpor strategi sought continu expand product servic offer
domest intern acquisit dental anim health medic product
distributor smaller scale compani also activ acquir practic manag
softwar provid acquisit activ pick recent year total acquisit invest
made respect acquisit
support hsic three-year compound annual growth rate ebitda view posit
asset growth slightli outpac ebitda growth result compani maintain
ebitda/asset ratio ebtda/equ ratio improv bp due
use leverag acquisit
april compani announc anim health product distribut segment spun
merg vet first choic form independ public compani vet first choic current
provid technology-en solut prescript manag softwar veterinari
practition busi combin offer full rang anim health suppli value-ad
servic custom receiv tax-fre dividend part deal
sharehold new entiti base compani guidanc expect ebit margin
improv spin-off dont expect meaning
impact overal organ growth rate beyond anim segment organ revenu
growth materi differ segment transact expect
complet end
financi trend hsic compound annual growth rate revenu ebitda
normal ep grew period ep growth aid
common stock repurchas ebitda growth ebitda margin
in-lin averag previou five year view hsic balanc sheet favor net
debt/ebitda debt/asset march decemb
compani use leverag support multipl acquisit one potenti concern
monitor come quarter inventori turnov fell march quarter
averag last four year
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next
month neutral base mainli
expect tepid growth prescript
drug volum continu
balanc solid growth fda novel drug
approv focu mainli drug
distribut busi compris
sale health care distribut
prescript drug volum seen meager
growth late expect even slower growth
come year
estim monthli prescript volum
level averag
obvious robust growth think
partli due slower growth
health-insur popul individu
health insur fill prescript
without estim growth
total enrolle major health insur
dip slightli neg territori
versu posit growth see
slower growth natur result
fewer peopl bring work forc
gain health insur expect
move forward given repeal
beyond weak growth prescript volum
deflat gener drug price gener
headwind distributor earn
case late growth gener drug
price averag around neg far
continu sever deflationari trend
forecast materi
improv gener drug price
next year either even though pace
gener approv seem slow
approv august versu
histor lower gener approv activ
tend lessen competit gener drug
maker lead increas gener price
howev expect deflat continu
less sever rate due signific
price power garner joint ventur
three major drug distributor
three largest retail pharmaci cardin
walgreen
although may seem counterintuit think
power jv exact price concess
gener maker hurt even drug
distributor apart jv
distributor fee often percentag
sale price trend view
distributor make volum
lost price enter jv
balanc neg see
sub-industri strong fda approv activ
novel drug fda approv new drug
increas
pace anoth strong year
alreadi approv octob
demand new drug potenti
signific tailwind drug
 health distributor index
fell vs rise
composit year-to-d
octob health
distributor vs
gain
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
versu /colin scarola
inc keep target price
ev/ebitda multipl roughli line long-term averag rais
ep estim ep
vs consensu report market share
gain help acceler jun-q sale growth yoy year ago
note howev growth pre-tax earn deprec amortiz
ebtda slow yoy due lower margin higher
interest expens despit strong pickup revenu growth
full-year guidanc rais think indic
continu margin pressur second half view market posit
growth outlook favor expect ebtda growth versu
remain cautiou share howev estim trade
premium forward ev/ebitda despit slower
growth outlook index /colin scarola
inc trim target price
ep estim slight discount three-year forward averag
price-to-earnings keep ep estim lower
report oper ep vs
consensu sale increas growth dental
increas anim health driven strong result intern market
announc spin anim health segment merg
sharehold approxim new compani vet first
choic sharehold own pend transact subject customari
close condit regulatori approv expect close end
view posit given unlock consider valu
analyst research note compani news
strong sell sell drop target
fy apr ep estim materi discount pdco
long-term forward price-to-earnings averag lower ep estim
earn releas schedul
today one day beforehand delay dec cite
need time evalu joint venture-rel non-oper incom
light recent account pronounc find time
delay vagu explan concern especi consid
fasb updat know relat topic impact report
period begin later also note releas
revenu today oper incom even though delay said
relat non-oper incom think indic bad news ahead
earn also see dividend unsustain cover
adj net incom earn downward trend /colin
inc rais target
ep estim line long-term averag forward price-to-earnings
keep ep estim rais ep
vs ahead consensu report
consecut quarter posit revenu growth yoy
exclud impact foreign currenc largest segment dental
total sale continu gain market share quarter increas sale
yoy local currenc largest percentag sale increas
quarter came technolog segment grew sale yoy follow
juli format practic manag softwar joint ventur internet
own think technolog jv unlock power
cross-sel opportun suppli busi tradit
competitor lack yet remain neutral share think
et cfra reiter sell opinion share patterson
compani inc lower target price
fy ep estim discount pdco
long-term averag think discount justifi neg earn
growth trend recent year see abat price pressur
continu lower ep estim
jul-q adj pre-tax earn yoy led dental
consum consecut quarter neg growth coupl
acceler margin pressur overal top-lin show growth
first time sinc due sale growth anim health segment
yet see near-term inflect toward earn growth trailing-twelv
anim health op inc yoy due margin pressur segment
well beyond risk upcom ftc trial octob see
consider risk dividend adj net incom less capital-expenditure fell well
short cover dividend second consecut quarter /colin
et cfra lower opinion share patterson compani inc
sell hold lower target price
forward price-to-earnings steep discount pdco long-term averag
think discount justifi neg earn growth trend
recent year see abat continu lose market share
lower apr ep estim
despit acquisit pdco earn tax
amort ebta fell yoy
respect also despit absorb lower margin organ growth dental
consum sale neg last quarter competitor
posit growth suspect
greater focu cross-sel softwar solut suppli
equip import factor market share gain
note term practic manag
softwar appear time recent earn call
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
